Purple Communications Product AgreementProduct Agreement • November 29th, 2023 • Texas
Thank you for ordering a Purple product (“Purple Product”) from Purple. We at Purple hope you will enjoy your use of your Purple Product. If you have any problems with your Purple Product, you can contact our Customer Experience Team at 877-885 -3172 through your Purple Product or phone or you can e-mail us at support@purple.us. In return, we ask that you (1) provide us with some general information about yourself and permit us to contact you from time to time to provide you information about our services and ask you for feedback on your particular Purple Product; (2) promise not to transfer your Purple Product to someone else; and (3) promise not to tamper with your Purple Product, or to let anyone else tamper with it. We hope you enjoy the ability to use your Purple Product to communicate with Deaf, Hard of Hearing, and/or hearing people anytime you want! This Agreement shall be deemed effective as of the date on which your Purple Product is installed and/or the date you first use yo
2 Drager/Aspect Product Agreement 20.04.99 - 2 -Product Agreement • January 27th, 2000 • Aspect Medical Systems Inc • Electromedical & electrotherapeutic apparatus
PRODUCT AGREEMENT #2 Pursuant to the MASTER AGREEMENT TO DEVELOP, PUBLISH AND SELL PRODUCT entered into between PEOPLE'S EDUCATION PRESS, ("PEP") and INTERNATIONAL ALPHA MEDIA, INC. ("Alpha") dated the 8th day of August 2000, the parties agree to...Product Agreement • February 4th, 2003 • Lingo Media Inc • Books: publishing or publishing & printing
MARCO UNIFYIT PRODUCT AGREEMENTProduct Agreement • January 21st, 2022
This Marco UnifyIT Product Agreement (“Product Agreement”) is entered into by and between Marco Technologies, LLC (“Marco”) and the legal entity identified in any Schedule of Products (“Client”) for the services (“Services”), equipment and other goods (collectively, “Equipment”), software (“Software”), and Incidentals (defined below) (collectively, “Products”) that Marco will provide during the Term and any Renewal Term of the Marco Relationship Agreement (“Agreement”) between Marco and Client. This Product Agreement is governed by and subject to the Agreement. Defined terms in the Agreement have the same meaning in this Product Agreement unless otherwise expressly stated. If Client does not accept and comply with this Product Agreement, it may not place an order or use the Products.
PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. REDACTED MATERIAL IS MARKED...Product Agreement • May 23rd, 2023 • Indivior PLC • Pharmaceutical preparations
This Product Agreement (this “Product Amendment”) is issued under the Master Manufacturing Services Agreement dated April 6, 2018 between Patheon Manufacturing Services LLC, and lndivior UK Limited (the “Master Agreement”), and is entered into on the date of last signature below (the “Effectlve Date”), between Patheon Manufacturing Services LLC, a limited liability company existing under the laws of the State of Delaware having a principal place of business at 5900 Martin Luther King Jr. Hwy, Greenville, NC 27834 ("Patheon") and lndivior UK Limited, incorporated and registered in England with company number 7183451 with its registered office at 103-105 Bath Road, Slough, Berkshire, SL1 3UH, United Kingdom ("lndivior").
Product AgreementProduct Agreement • February 22nd, 2018 • CAT9 Group Inc. • Blank checks
According to relevant national laws, regulations, based on equality, mutual benefit, and friend negotiation, Party A and Party B reached the following agreement:
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. PRODUCT AGREEMENT (Includes Schedules A to E)...Product Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • Delaware
This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated August 21, 2014 between Patheon Pharmaceuticals Inc., and Osmotica Pharmaceutical Corp., (the “Master Agreement”), and is entered into October 1, 2014 (the “Effective Date”), between Patheon Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, having a principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237-1626 (“Patheon”) and Osmotica Pharmaceutical Corp., a corporation existing under the laws of the State of Delaware, having a principal place of business at 895 Sawyer Road, Marietta, GA 30062 (“Client”).
TERMS AND CONDITIONS OF FORTUM MAINIO PRODUCT AGREEMENT 1 APRIL 2023Product Agreement • February 6th, 2023
First Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • August 4th, 2016 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment to Product Agreement (the “Amendment”), dated April 25, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
This agreement is between:Product Agreement • May 16th, 2002
CardioGenics And Merck In Second Product AgreementProduct Agreement • July 15th, 2010 • CardioGenics Holdings Inc. • Services-business services, nec
This is the second product agreement between the two companies. The first covers a 10-year supply agreement for CardioGenics‘ silver-coated magnetic beads that Merck will distribute to manufacturers of medical laboratory analyzers.
PRODUCT AGREEMENTProduct Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
Pursuant to the Master Manufacturing Services Agreement dated August 3, 2015 between Patheon Pharmaceuticals Inc., and Acadia Pharmaceuticals Inc., as amended January 1, 2022 (collectively the “Master Agreement”), this Product Agreement (this “Product Agreement” or “PA”) is effective as of May 1, 2022 (the “Effective Date”), and is entered into by Acadia Pharmaceuticals Inc., a Delaware corporation having its principal place of business at 12830 El Camino Real, Suite 400, San Diego, California 92130 ( “Acadia” or “Client”), and Patheon Pharmaceuticals Inc., having a principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237( “Patheon”) on behalf of itself and its Affiliates, as defined in Section 1.3 of the Master Agreement) within the Thermo Fisher Scientific Inc. Pharma Services Group. Patheon and Acadia may be collectively referred to as the parties and individually as a party.
Inscape Imagery Product AgreementProduct Agreement • August 2nd, 2021
This Agreement is a legally binding contract between Inscape Imagery, (hereafter “THE PHOTOGRAPHER”) and the undersigned hereafter referred to as “THECLIENT).
StreamlineIT Product AgreementProduct Agreement • October 31st, 2016
First Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • May 6th, 2021 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment to Product Agreement (the “Amendment”), dated April 25, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
AMENDED & RESTATED AMENDMENT NUMBER 1 TO PRODUCT AGREEMENT (Hunter: The Reckoning For Xbox and PS2)Product Agreement • May 15th, 2002 • Interplay Entertainment Corp • Services-prepackaged software
Final termsProduct Agreement • August 19th, 2016
Product Agreement– Capped Floored FRN Final Documentation 19 August, 2016 Currency USD Maturity 3 Years Capital guarantee at maturity 100 %
PRODUCT AGREEMENT VARUBI (ROLAPITANT TABLETS 100 mg)Product Agreement • February 29th, 2016 • TESARO, Inc. • Pharmaceutical preparations • Ontario
This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated October 13th, 2015 between Patheon Inc. and TESARO, Inc. (the “Master Agreement”), and is entered into October 13th, 2015 (the “Effective Date”), between Patheon Inc., a corporation existing under the laws of Canada , having a principal place of business at 2100 Syntex Court, Mississauga, Ontario, L5N 7K9 (“Patheon”), and TESARO, Inc., a corporation existing under the laws of the State of Delaware, USA, having a principal place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts, USA (“Client”).
Product Agreement Genpak LLCProduct Agreement • January 9th, 2015
Genpak LLC represents and warrants to you that the products being sold by us to you as of the date of the shipment by us for delivery to you are not adulterated or misbranded or an article which can not be introduced into interstate commerce, all in compliance with the applicable sections of the Federal Food, Drug and Cosmetic Act. We further represent to you that we are in compliance with all applicable federal, state and local laws relating to the manufacture of our product, the content of our product complies in all respects with the Federal Food, Drug and Cosmetic Act and the applicable sections thereto.
EXHIBIT 4.9 (PROTHERICS LOGO) Swedish Orphan AB Dtottninggatan 98 S-11160 Stockholm Sweden 14 November 2003 Dear Sirs, Product Agreement dated January 1990 between Swedish Orphan AB (now Swedish Orphan International AB) and Therapeutic Antibodies...Product Agreement • September 30th, 2004 • Protherics PLC • Pharmaceutical preparations
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Product Agreement • May 11th, 2023 • Amylyx Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 2, is effective as of March 20th, 2023 (“Effective Date”) by and between Amylyx Pharmaceuticals, Inc., having a principal place of business of business at 43 Thorndike Street, Cambridge, MA 02141 (“Client”) and Patheon Inc., having a principal place of businessat 111 Consumers Drive, Whitby, Ontario, L1N 5Z5 (“Patheon”).
PRODUCT AGREEMENT (INGREZZATM (valbenazine))Product Agreement • April 25th, 2017 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances) • California
This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated 28 November 2016 between Patheon UK Limited and Neurocrine Biosciences Inc. (the “Master Agreement”), and is entered into 28 November 2016 (the “Effective Date”), between Patheon UK Limited, a corporation existing under the laws of England, having a principal place of business at Kingfisher Drive, Covingham, Swindon, SN3 5BZ, England (“Patheon”) and Neurocrine Biosciences Inc, 12780 El Camino Real, San Diego 92130, California, USA (“Client”).
Product AgreementProduct Agreement • August 1st, 2024 • AmpliTech Group, Inc. • Communications equipment, nec
This [***] Product Agreement (hereinafter referred to as the “Agreement”) is made at [***] and entered into effective as of 26 day of July 2024 (the “Effective Date”)
SE M T SAProduct Agreement • September 9th, 2022
Product AgreementProduct Agreement • November 21st, 2002 • Rf Monolithics Inc /De/ • Radio & tv broadcasting & communications equipment • Texas
This Product Agreement (this “Agreement”) is made as of September 1, 2002 (the “Effective Date”) by and between TAI-SAW Technology Co., Ltd., a corporation duly organized and existing under the laws of Taiwan (R.O.C.) with its principal place of business at No. 3, Industrial 2nd Rd., Ping-Chen Industrial District, Tao Yuan, 324, Taiwan, R.O.C. (TST”), and RF Monolithics, Inc., a corporation duly organized under the laws of the state of Delaware, having its principal place of business at 4347 Sigma Road, Dallas, TX, 75244, U.S.A. (“RFM”) (collectively, the “Parties”).
Product AgreementProduct Agreement • February 21st, 2022
(the “Privacy Policy”) (collectively, the “Agreement”), as use of an OSAP course or other product (each a “Product”) constitutes your acceptance of the terms of this Agreement. If you do not agree to the terms of this Agreement, then you may not access or use any Product. You represent and warrant that you have the legal authority to bind yourself to the terms of this Agreement. You acknowledge and agree that you have read and are hereby bound by this Agreement and agree to comply with all applicable laws, regulations and/or rules with regard to your use of the Products. “Learner” means you, as the person using the applicable Product. “Purchaser” means the person or entity that purchased the right to use that Product. Learner hereby agrees to the following:
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER...Product Agreement • April 24th, 2024 • Calliditas Therapeutics AB • Pharmaceutical preparations
This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated December 30, 2020 between Patheon Pharmaceuticals Inc. and Calliditas Therapeutics AB (the “Master Agreement”), and is entered into on December 30, 2020 (the “Effective Date”) between Patheon Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, with its principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237 (“Patheon”) and Calliditas Therapeutics AB, a company existing under the laws of Sweden, with its principal place of business at Kungsbron 1, C8, SE-111 22 Stockholm (“Client”). For the purpose of this Product Agreement, references in the Master Agreement to “Patheon” and “Client” mean the entities defined respectively as Patheon and Client in this Product Agreement.
PRODUCT AGREEMENT (Includes Schedules A to D) PRODUCT AGREEMENTProduct Agreement • August 10th, 2020 • ChemoCentryx, Inc. • Pharmaceutical preparations • Delaware
This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated March 18, 2020 between Patheon Pharmaceuticals Inc., and ChemoCentryx, Inc., (the “Master Agreement”), and is entered into as of the last signature date set forth below (the “Effective Date”), between Patheon Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, having a principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237-1625 (“Patheon”) and ChemoCentryx, Inc., a corporation existing under the laws of the State of Delaware having a principal place of business at 850 Maude Avenue, Mountain View, CA 94043 USA (“Client”).
AMENDMENT AGREEMENT – AMENDMENT NO.4 TO THE PRODUCT AGREEMENT DATED JULY 28, 2017Product Agreement • March 14th, 2022 • Paratek Pharmaceuticals, Inc. • Pharmaceutical preparations
CUSTOMER APPLICATION PACKAGE (CAP) INCLUDING TX PRODUCT AGREEMENTProduct Agreement • November 20th, 2020
DataTrax Services LLC (DataTrax) PO Box 451154 Houston TX 77245-1154, has established databases available for access by its Customers pursuant to the terms and conditions of this agreement. Customer desires to obtain access to DataTrax’s databases, and DataTrax will grant such access, provided certain contractual terms and conditions are met. Therefore, in consideration of the promises made in this Agreement, DataTrax and Customer agree as follows:
AMENDMENT AGREEMENT – AMENDMENT NO. 2 TO THE PRODUCT AGREEMENT DATED JULY 28, 2017Product Agreement • January 4th, 2021 • Paratek Pharmaceuticals, Inc. • Pharmaceutical preparations
Second Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • May 6th, 2021 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This Second Amendment to Product Agreement (the “Amendment”), dated October 6, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
AMENDED AND RESTATED PRODUCT AGREEMENT (INGREZZATM (valbenazine))Product Agreement • November 1st, 2017 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances)
This Amended and Restated Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated 28 November 2016 between Patheon UK Limited and Neurocrine Biosciences Inc. (the “Master Agreement”), and is entered into 27 June 2017 (the “Effective Date”), between Patheon UK Limited, a corporation existing under the laws of England, having a principal place of business at Kingfisher Drive, Covingham, Swindon, SN3 5BZ, England (“Patheon”) and Neurocrine Biosciences Inc, 12780 El Camino Real, San Diego 92130, California, USA (“Client”).
Second Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • November 7th, 2016 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This Second Amendment to Product Agreement (the “Amendment”), dated October 6, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
First Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment to Product Agreement (the “Amendment”), dated April 25, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
